Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies
Status:
Completed
Trial end date:
2018-09-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the multiple-dose safety and tolerability
profile of TAK-935 in adult participants with developmental and/or epileptic
encephalopathies.